Somatostatin Analogues Market - By Type (Octreotide, Lanreotide, Pasireotide), By Application (Acromegaly, Carcinoid Syndrome, Neuroendocrine Tumor, Cushing Syndrome, Others), By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Industry Analysis, opportunity and Forecast 2020 To 2027
Published Date: May 2021
No. of Pages: 188
Status: Published
Report Code: ARI100364
Some of the factors driving the growth of the demand for somatostatin analogues are growing R&D initiatives and the release of novel drug therapies. For starters, Novartis AG introduced Signifor (Pasireotide) in 2012 to treat Cushing's syndrome and acromegaly in 2014. Another key contributing factor to overall market growth is the presence of favourable government insurance policies & schemes for rare disease patients. For example, multiple government healthcare agencies in the U.S. and Europe, such as National Institutes of Health (NIH) and National Centre of Advancing Translational Sciences (NCATS), provide affordable rare disease medicines.
Increasing efforts to increase awareness about Acromegaly. In November 2017, the World Alliance of Pituitary Organizations (WAPO) launched a global awareness campaign, in which November 1st is celebrated as the Acromegaly Awareness Day every year. The main purpose of this campaign is to raise awareness about the rare disease and reduce the time it takes to get a diagnosis for people with Acromegaly.
In terms of market players, the key players within global Somatostatin Analogues market include. Sun Pharmaceutical In dustries Ltd, Pfizer Inc., Camurus AB, Chiasma Inc., Crenetics Pharmaceuticals, Dauntless Pharmaceuticals, Ipsen Pharma, Midatech Pharma PLC, Novartis AG, Peptron, Inc., and Teva Pharmaceuticals Inc amongst others.
Analyst Commentary
The Somatostatin Analogues market, according to this research study, has been touted to emerge as one of the most productive industry verticals in the forthcoming years. The research report forecasts the Somatostatin Analogues market to accumulate substantial returns by the end of the projected duration, registering a substantial annual growth rate over the forecast period.
The somatostatin analogues market is competitive and fragmented in nature with the existence of a major somatostatin analogues suppliers and a huge number of small players. The leading players in the market are growing their scope by increasing their focus on the new technologies, innovation and research and development activities to increase the efficiency of somatostatin analogues.
The major companies are focused on improving brand positioning by constant innovations, product differentiation and introducing new drugs for the treatment of non-operable tumors. They are taking major initiatives to introduce clinical trials for testing of new somatostatin analogues.
Based on indication, the market is segmented into acromegaly, NETs, and others. Acromegaly is projected to be the largest segment over the forecast period in 2018 and the fastest growing segment. Increasing understanding of acromegaly coupled with the availability of effective treatment options is considered the major factor driving the segment's development. Acromegaly Awareness Day, for example, was celebrated in Canada in November 2018, offering different acromegaly facts along with available treatment services and benefits.
Segmentation
The global Somatostatin Analogues market is categorized into two categories; which are on the basis of type and secondly on the basis of application. When it comes to bifurcation by type, the octreotide segment continues to dominate the global market among other type segments in terms of revenue share. This can be attributed to its different therapeutic applications such as carcinoid tumors, acromegaly, and vasoactive intestinal peptide tumors. Pasireotide is projected to be fastest-growing segment in terms of revenue share over the forecast period, which is attributed to its efficacy in patients with acromegaly and Cushing syndrome.
When it comes to segmentation on the basis of application, the acromegaly segment among the application segments is expected to continue its dominance in terms of revenue share over the forecast period. This segment is also expected to be fastest growing segment in terms of revenue share over the forecast period. This can be attributed to growing awareness of acromegaly and availability of various effective treatment options.
Regional Analysis
The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa with its further bifurcation into major countries such as US, Canada, Germany, UK, France, China, Japan, India, GCC countries, Brazil Countries such as the US and Canada have been at the forefront of the healthcare industry over the years. High awareness about NETs, high per capita disposable income, and the emergence of new companies such as Crinetics Pharmaceuticals and Chiasma, Inc., among others for development of the generic versions of the somatostatin analogs are some of the contributing factors for the growth of the somatostatin analogs market in this region. Europe is the second-largest market for somatostatin analogs. High revenues generated by the major market players such as Novartis AG and Ipsen Pharma, among others are influencing the growth of the regional market and increasing prevalence of Acromegaly and NETs is also creating the demand for the treatment options resulting in the growth in the region. For instance, each year, about 300 new patients are diagnosed with Acromegaly in Germany
The Asia-Pacific region is anticipated to be the fastest-growing region in the global somatostatin analogs market. This region has been witnessing an increase in the number of people afflicted with acromegaly and NETs. In 2018, about 22,402 new cases of pancreatic cancer were registered in South East Asia. The increasing prevalence of these diseases is an important factor in the growth of the somatostatin analogs market in Asia-Pacific region. Middle East and Africa is the smallest market due to limited healthcare infrastructure, lack of awareness about the disease condition, and low per capita disposable incomes in underdeveloped regions of Africa.
TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary data mining
2.3.2. Primary Sources
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Global Somatostatin Analogs Market
Chapter 5. Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
5.1. Global Somatostatin Analogs Market Share, By Type, 2015 - 2027 (USD Million)
5.1.1. Octreotide
5.1.1.1. Market Size and Projections,2015 - 2027 (USD Million)
5.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.2. Lanreotide
5.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.3. Pasireotide
5.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 6. Global Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
6.1. Global Somatostatin Analogs Share, By Application, 2015 - 2027 (USD Million)
6.1.1. Acromegaly
6.1.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.2. Carcinoid Syndrome
6.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.3. Neuroendocrine Tumor
6.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.4. Cushing Syndrome
6.1.4.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.4.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.5. Others
6.1.5.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.5.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 7. Global Somatostatin Analogs Market Overview, By Geography, 2015 – 2027 (USD Million)
7.1. Global Somatostatin Analogs Market Share, By Geography, 2015 - 2027 (USD Million)
7.1.1. Market Size and projections, by Countries, 2015 – 2027 (USD Million)
7.1.2. Market Share and CAGR Comparison, by Countries, 2019 (%)
Chapter 8. North America Global Somatostatin Analogs Market Overview, By Countries, 2015 - 2027 (USD Million)
8.1. North America Global Somatostatin Analogs Market Overview, 2015 - 2027 (USD Million)
8.1.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.2. North America Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
8.1.3. North America Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
8.1.4. North America Global Somatostatin Analogs Market Overview, By Countries, 2015 - 2027 (USD Million)
8.1.4.1. U.S. Global Somatostatin Analogs Market Overview, 2015 - 2027 (USD Million)
8.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.4.1.2. U.S. Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
8.1.4.1.3. U.S. Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
8.1.4.2. Canada Global Somatostatin Analogs Market Overview, 2015 - 2027 (USD Million)
8.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.4.2.2. Canada Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
8.1.4.2.3. Canada Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
8.1.4.3. Mexico Global Somatostatin Analogs Market Overview, 2015 - 2027 (USD Million)
8.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.4.3.2. Mexico Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
8.1.4.3.3. Mexico Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
Chapter 9. Europe Global Somatostatin Analogs Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1. Europe Global Somatostatin Analogs Market Overview, 2015 – 2027 (USD Million)
9.1.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.2. Europe Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.3. Europe Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
9.1.4. Europe Global Somatostatin Analogs Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1.4.1. Germany
9.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.1.2. Germany Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.4.1.3. Germany Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
9.1.4.2. France
9.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.2.2. France Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.4.2.3. France Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
9.1.4.3. UK
9.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.3.2. UK Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.4.3.3. UK Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
9.1.4.4. Italy
9.1.4.4.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.4.2. Italy Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.4.4.3. Italy Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
9.1.4.5. Spain
9.1.4.5.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.5.2. Spain Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.4.5.3. Spain Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
9.1.4.6. Rest of Europe
9.1.4.6.1. Market size and projections, 2015 – 2025
9.1.4.6.2. Rest of Europe Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.4.6.3. Rest of Europe Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
Chapter 10. Asia Pacific Global Somatostatin Analogs Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1. Asia Pacific Somatostatin Analogs Market Overview, 2015 - 2027 (USD Million)
10.1.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.2. Asia Pacific Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.3. Asia Pacific Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
10.1.4. Asia Pacific Global Somatostatin Analogs Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1.4.1. India
10.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.1.2. India Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.4.1.3. India Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
10.1.4.2. China
10.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.2.2. China Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.4.2.3. China Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
10.1.4.3. Japan
10.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.3.2. Japan Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.4.3.3. Japan Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
10.1.4.4. South Korea
10.1.4.4.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.4.2. South Korea Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.4.4.3. South Korea Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
10.1.4.5. Rest of Asia Pacific
10.1.4.5.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.5.2. Rest of Asia Pacific Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.4.5.3. Rest of Asia Pacific Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
Chapter 11. Middle East & Africa Global Somatostatin Analogs Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1. Middle East & Africa Global Somatostatin Analogs Market Overview, 2015 - 2027 (USD Million)
11.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.2. Middle East & Africa Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.3. Middle East & Africa Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
11.1.4. Middle East & Africa Global Somatostatin Analogs Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1.4.1. GCC
11.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.4.1.2. GCC Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.4.1.3. GCC Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
11.1.4.2. South Africa
11.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.4.2.2. South Africa Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.4.2.3. South Africa Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
11.1.4.3. Rest of Middle East & Africa
11.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.4.3.2. Rest of Middle East & Africa Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.4.3.3. Rest of Middle East & Africa Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
Chapter 12. South America Global Somatostatin Analogs Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1. South America Global Somatostatin Analogs Market Overview, 2015 - 2027 (USD Million)
12.1.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.2. South America Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.3. South America Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
12.1.4. South America Global Somatostatin Analogs Market Overview, By Countries, 2015- 2026 (USD Million)
12.1.4.1. Brazil
12.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.4.1.2. Brazil Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.4.1.3. Brazil Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
12.1.4.2. Argentina
12.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.4.2.2. Argentina Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.4.2.3. Argentina Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
12.1.4.3. Rest of South America
12.1.4.3.1. Market size and projections, 2015 – 2026
12.1.4.3.2. Rest of South America Global Somatostatin Analogs Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.4.3.3. Rest of South America Somatostatin Analogs Market Overview, By Application, 2015 - 2027 (USD Million)
Chapter 13. Competitive Landscape
13.1. Competitive environment, 2020
13.2. Strategic framework
13.2.1. Partnership/agreement
13.2.2. Expansion
13.2.3. Mergers & Acquisitions
13.2.4. New Type development
Chapter 14. Key Application Analysis
14.1. Sun Pharmaceutical Industries Ltd.
14.1.1. Company overview
14.1.2. Financial performance
14.1.3. Type Benchmarking
14.1.4. Recent initiatives
14.1.5. SWOT analysis
14.2. Camurus AB
14.2.1. Company overview
14.2.2. Financial performance
14.2.3. Type Benchmarking
14.2.4. Recent initiatives
14.2.5. SWOT analysis
14.3. Dauntless Pharmaceuticals
14.4. Crenetics Pharmaceuticals
14.5. Novartis AG
14.6. IPSEN Pharma
14.7. Midatech Pharma
Chapter 15. Global Somatostatin Analogs Market Cost Analysis
15.1. Global Somatostatin Analogs Market Key Raw Materials Analysis
15.1.1. Key Raw Materials
15.1.2. Price Trend of Key Raw Materials
15.1.3. Key Suppliers of Raw Materials
15.1.4. Market Concentration Rate of Raw Materials
15.2. Proportion of Wing Cost Structure
15.2.1. Raw Materials
15.2.2. Labor Cost
15.2.3. Wing Expenses
15.3. Wing Process Analysis of Unsaturated Polyester Resin (UPR) for Composites
Chapter 16. Chain, Sourcing Strategy and Downstream Buyers
16.1. Global Somatostatin Analogs Market Chain Analysis
16.2. Upstream Raw Materials Sourcing
16.3. Raw Materials Sources of Global Somatostatin Analogs Market Major Manufacturers in 2019
16.4. Downstream Buyers
Chapter 17. Marketing Strategy Analysis, Distributors/Traders
17.1. Marketing Channel
17.1.1. Direct Marketing
17.1.2. Indirect Marketing
17.1.3. Marketing Channel Development Trend
17.2. Market Positioning
17.2.1. Pricing Strategy
17.2.2. Brand Strategy
17.2.3. Target Electrical Damage
17.3. Distributors/Traders List
Chapter 18. Market Effect Factors Analysis
18.1. Type Progress/Risk
18.1.1. Substitutes Threat
18.1.2. Type Progress in Related Industry
18.2. Consumer Needs/Customer Preference Change
18.3. Economic/Political Environmental Change
Chapter 19. Future Outlook of the Market
Disclaimer
List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Somatostatin Analogs Market share, by Type, 2020 & 2027 (%)
10. Global Somatostatin Analogs Market share, by Type 2020 & 2027 (USD Million)
11. Global Somatostatin Analogs Market share, by Octreotide, by Type, 2020 & 2027 (USD Million)
12. Global Somatostatin Analogs Market share, by Lanreotide, by Type, 2020 & 2027 (USD Million)
13. Global Somatostatin Analogs Market share, by Pasireotide, by Type, 2020 & 2027 (USD Million)
14. Global Somatostatin Analogs Market share, by Application, 2020 & 2027 (%)
15. Global Somatostatin Analogs Market share, by Acromegaly, by Application, 2020 & 2027 (USD Million)
16. Global Somatostatin Analogs Market share, by Carcinoid Syndrome, by Application, 2020 & 2027 (USD Million)
17. Global Somatostatin Analogs Market share, by Neuroendocrine Tumor, by Application, 2020 & 2027 (USD Million)
18. Global Somatostatin Analogs Market share, by Cushing Syndrome, by Application, 2020 & 2027 (USD Million)
19. Global Somatostatin Analogs Market share, by Other, by Application, 2020 & 2027 (USD Million)
20. Global Somatostatin Analogs Market share, by region, 2020 - 2027(%)
21. Global Somatostatin Analogs Market share, by region, 2019 - 2027(USD Million)
22. North America Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
23. North America Global Somatostatin Analogs Market share, by Countries, 2020 & 2027 (%)
24. U.S. Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
25. Canada Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
26. Europe Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
27. Europe Global Somatostatin Analogs Market share, by Countries, 2020 & 2027 (%)
28. Spain Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
29. UK Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
30. Italy Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
31. Germany Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
32. France Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
33. Rest of Europe Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
34. Asia-Pacific Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
35. Asia-Pacific Global Somatostatin Analogs Market share, by Countries, 2020 & 2027 (%)
36. China Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
37. India Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
38. Australia Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
39. Japan Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
40. Rest of Asia-Pacific Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
41. Middle East & Africa Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
42. Middle East & Africa Global Somatostatin Analogs Market share, by Countries, 2020 & 2027 (%)
43. GCC Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
44. South Africa Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
45. Rest of Middle East & Africa Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
46. South America Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
47. Brazil Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
48. Mexico Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
49. Argentina Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
50. Rest Of South America Global Somatostatin Analogs Market, 2020 - 2027(USD Million)
List of Tables
1. Impact of Market drivers
2. Impact of Market restraints
3. Global Somatostatin Analogs Market, 2020-2027 (USD Million)
4. Somatostatin Analogs requirement, by country, 2020-2027, (USD Million)
5. North America Global Somatostatin Analogs Market, by Type, 2020-2027 (USD Million)
6. North America Global Somatostatin Analogs Market, by Application, 2020-2027 (USD Million)
7. Europe Global Somatostatin Analogs Market, by Type, 2020-2027 (USD Million)
8. Europe Global Somatostatin Analogs Market, by Application, 2020-2027 (USD Million)
9. Asia Pacific Global Somatostatin Analogs Market, by Type, 2020-2027 (USD Million)
10. Asia Pacific Global Somatostatin Analogs Market, by Application, 2020-2027 (USD Million)
11. Middle East & Africa Global Somatostatin Analogs Market, by Type, 2020-2027 (USD Million)
12. Middle East & Africa Global Somatostatin Analogs Market, by Application, 2020-2027 (USD Million)
13. South America Global Somatostatin Analogs Market, by Type, 2020-2027 (USD Million)
14. South America Global Somatostatin Analogs Market, by Application, 2020-2027 (USD Million)
15. Global Somatostatin Analogs Market, Company Market Share, 2018 (%)
16. SUN PHARMACEUTICAL INDUSTRIES LTD : Product Benchmarking
17. SUN PHARMACEUTICAL INDUSTRIES LTD : Financial Performance
18. Camurus AB: Product Benchmarking
19. Camurus AB: Financial Performance
20. Dauntless Pharmaceuticals: Product Benchmarking
21. Dauntless Pharmaceuticals: Financial Performance
22. Crenetics Pharmaceuticals: Product Benchmarking
23. Crenetics Pharmaceuticals: Financial Performance
24. Novartis AG: Product Benchmarking
25. Novartis AG: Financial Performance
26. Ipsen Pharma: Product Benchmarking
27. Ipsen Pharma: Financial Performance
28. Midatech Pharma: Product Benchmarking
29. Midatech Pharma: Financial Performance
30. Teva Pharmaceuticals Inc: Product Benchmarking
31. Teva Pharmaceuticals Inc: Financial Performance
The Leading Key Players in Somatostatin Analogues Market
Sun Pharmaceutical In dustries Ltd
Pfizer Inc.
Camurus AB
Chiasma Inc.
Crenetics Pharmaceuticals
Dauntless Pharmaceuticals
Ipsen Pharma
Midatech Pharma PLC
Novartis AG
Peptron Inc.
Teva Pharmaceuticals Inc amongst others.
